FR3014693B1 - Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales - Google Patents

Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales

Info

Publication number
FR3014693B1
FR3014693B1 FR1362682A FR1362682A FR3014693B1 FR 3014693 B1 FR3014693 B1 FR 3014693B1 FR 1362682 A FR1362682 A FR 1362682A FR 1362682 A FR1362682 A FR 1362682A FR 3014693 B1 FR3014693 B1 FR 3014693B1
Authority
FR
France
Prior art keywords
pelvi
propenone
piperazin
fluoro
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1362682A
Other languages
English (en)
Other versions
FR3014693A1 (fr
Inventor
Grand Bruno Le
Didier Junquero
Nicolas Monjotin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1362682A priority Critical patent/FR3014693B1/fr
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to CN201480068095.9A priority patent/CN105813642B/zh
Priority to AU2014365665A priority patent/AU2014365665B2/en
Priority to EP14793086.1A priority patent/EP3082818A1/fr
Priority to US15/101,170 priority patent/US9980970B2/en
Priority to UAA201607312A priority patent/UA120603C2/uk
Priority to MX2016007795A priority patent/MX370061B/es
Priority to MA39072A priority patent/MA39072A1/fr
Priority to CA2931161A priority patent/CA2931161A1/fr
Priority to JP2016540042A priority patent/JP6612233B2/ja
Priority to KR1020167017262A priority patent/KR20160089518A/ko
Priority to PCT/EP2014/073453 priority patent/WO2015090705A1/fr
Priority to TN2016000196A priority patent/TN2016000196A1/fr
Priority to RU2016127158A priority patent/RU2678309C1/ru
Publication of FR3014693A1 publication Critical patent/FR3014693A1/fr
Publication of FR3014693B1 publication Critical patent/FR3014693B1/fr
Application granted granted Critical
Priority to IL246216A priority patent/IL246216A0/en
Priority to SA516371348A priority patent/SA516371348B1/ar
Priority to HK16110155.2A priority patent/HK1221913A1/zh
Priority to US15/962,837 priority patent/US10265322B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Abstract

La présente invention concerne l'utilisation de la 3- (2-Chloro-phényl ) -1- [4- (4-fluoro-benzyl) -pipérazin-1-yl ] -propénone ou l'un de ses sels pharmaceutiquement acceptables pour la prévention et/ou le traitement des pathologies fonctionnelles pelvi-périnéales, notamment du syndrome de la vessie douloureuse.
FR1362682A 2013-12-16 2013-12-16 Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales Expired - Fee Related FR3014693B1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FR1362682A FR3014693B1 (fr) 2013-12-16 2013-12-16 Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
TN2016000196A TN2016000196A1 (fr) 2013-12-16 2014-10-31 Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales.
AU2014365665A AU2014365665B2 (en) 2013-12-16 2014-10-31 Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions
US15/101,170 US9980970B2 (en) 2013-12-16 2014-10-31 Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions
UAA201607312A UA120603C2 (uk) 2013-12-16 2014-10-31 Застосування антагоністів, що активуються протеазою рецепторів 1 (par1), для профілактики та/або лікування функціональних патологічних станів в області таза і промежини
MX2016007795A MX370061B (es) 2013-12-16 2014-10-31 Uso de antagonistas del par-1 para prevenir y/o tratar condiciones patologicas funcionales pelviperineales.
MA39072A MA39072A1 (fr) 2013-12-16 2014-10-31 Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
CA2931161A CA2931161A1 (fr) 2013-12-16 2014-10-31 Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
RU2016127158A RU2678309C1 (ru) 2013-12-16 2014-10-31 Применение антагонистов активируемых протеазой рецепторов 1 (par-1) для профилактики и/или лечения функциональных патологических состояний в области таза и промежности
KR1020167017262A KR20160089518A (ko) 2013-12-16 2014-10-31 골반-회음부 기능의 병리학적 병태들을 예방하고/거나 치료하기 위한 par-1 길항제들의 용도
CN201480068095.9A CN105813642B (zh) 2013-12-16 2014-10-31 Par-1拮抗剂用于预防和/或治疗骨盆-会阴功能病状的用途
EP14793086.1A EP3082818A1 (fr) 2013-12-16 2014-10-31 Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
JP2016540042A JP6612233B2 (ja) 2013-12-16 2014-10-31 骨盤・会陰部機能の病的状態を予防および／または治療するためのｐａｒ−１アンタゴニストの使用
PCT/EP2014/073453 WO2015090705A1 (fr) 2013-12-16 2014-10-31 Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
IL246216A IL246216A0 (en) 2013-12-16 2016-06-14 Use of par-1 antagonists for the prevention and/or treatment of functional and pathological conditions of the pelvic-perianal
SA516371348A SA516371348B1 (ar) 2013-12-16 2016-06-16 استعمال مضادات par-1 للوقاية من و/أو علاج الحالات المرضيه الوظيفية لمنطقة الحوض والعِجان
HK16110155.2A HK1221913A1 (zh) 2013-12-16 2016-08-25 拮抗劑用於預防和/或治療骨盆-會陰功能病狀的用途
US15/962,837 US10265322B2 (en) 2013-12-16 2018-04-25 Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1362682A FR3014693B1 (fr) 2013-12-16 2013-12-16 Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales

Publications (2)

Publication Number Publication Date
FR3014693A1 FR3014693A1 (fr) 2015-06-19
FR3014693B1 true FR3014693B1 (fr) 2016-01-08

Family

ID=50424483

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1362682A Expired - Fee Related FR3014693B1 (fr) 2013-12-16 2013-12-16 Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales

Country Status (17)

Country Link
US (2) US9980970B2 (fr)
EP (1) EP3082818A1 (fr)
JP (1) JP6612233B2 (fr)
KR (1) KR20160089518A (fr)
CN (1) CN105813642B (fr)
AU (1) AU2014365665B2 (fr)
CA (1) CA2931161A1 (fr)
FR (1) FR3014693B1 (fr)
HK (1) HK1221913A1 (fr)
IL (1) IL246216A0 (fr)
MA (1) MA39072A1 (fr)
MX (1) MX370061B (fr)
RU (1) RU2678309C1 (fr)
SA (1) SA516371348B1 (fr)
TN (1) TN2016000196A1 (fr)
UA (1) UA120603C2 (fr)
WO (1) WO2015090705A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3090317B1 (fr) * 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110393718B (zh) * 2019-08-20 2022-10-04 青岛海洋生物医药研究院 阿托帕沙溴酸作为新型jak-stat3信号通路抑制剂的用途和研究方法
FR3109089B1 (fr) * 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089428A1 (fr) 2002-04-16 2003-10-30 Schering Corporation Antagonistes tricycliques du recepteur de thrombine
JP2008519039A (ja) * 2004-11-04 2008-06-05 ニュー イングランド メデカル センター ホスピタルズ インク Ｇタンパク質共役型受容体アゴニストおよびアンタゴニストならびに使用方法
FR2902426B1 (fr) * 2006-06-19 2008-09-05 Pierre Fabre Medicament Sa Derives de cinnamoyl-piperazine
EP2709630A4 (fr) * 2011-05-12 2014-10-22 UNIVERSITé LAVAL Inhibiteurs de par1 destinés à être utilisés dans le traitement ou la prévention d'infections par paramyxoviridae
RU2468759C1 (ru) * 2011-09-23 2012-12-10 Ольга Викторовна Тарабанова Способ лечения нарушений анатомических соотношений органов малого таза у женщин с атрофией мышц, поднимающих задний проход, и/или множественными дефектами ректо-вагинальной фасции

Also Published As

Publication number Publication date
CN105813642A (zh) 2016-07-27
JP6612233B2 (ja) 2019-11-27
JP2016540799A (ja) 2016-12-28
CA2931161A1 (fr) 2015-06-25
AU2014365665B2 (en) 2019-08-29
FR3014693A1 (fr) 2015-06-19
US10265322B2 (en) 2019-04-23
EP3082818A1 (fr) 2016-10-26
HK1221913A1 (zh) 2017-06-16
US20160287603A1 (en) 2016-10-06
AU2014365665A1 (en) 2016-07-14
WO2015090705A1 (fr) 2015-06-25
KR20160089518A (ko) 2016-07-27
US20180311253A1 (en) 2018-11-01
MA39072A1 (fr) 2017-05-31
UA120603C2 (uk) 2020-01-10
MX370061B (es) 2019-11-29
MX2016007795A (es) 2016-09-07
CN105813642B (zh) 2019-05-03
RU2678309C1 (ru) 2019-01-25
US9980970B2 (en) 2018-05-29
IL246216A0 (en) 2016-07-31
SA516371348B1 (ar) 2019-11-10
TN2016000196A1 (fr) 2017-10-06

Similar Documents

Publication Publication Date Title
PH12016500024A1 (en) Bromodomain inhibitor
IN2015DN01156A (fr)
EA201500362A1 (ru) Ингибиторы rho-киназы
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
TR201901886T4 (tr) DNA-PK inhibitörleri.
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
TR201819092T4 (tr) Serin proteaz inhibitörleri olarak multi-sübstüte edilmiş aromatik bileşikler.
MX2009006823A (es) Formas de dosificacion solidas de desintegracion oral que comprenden progestina y metodos para hacer y usar las mismas.
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
UY32380A (es) Combinaciones que comprenden metotrexato e inhibidores de dhodh
TR201911232T4 (tr) Otoimmünite gelişimine yönelik coriolus versicolorun ekstraktını içeren topikal bileşimler.
MA35638B1 (fr) 2-thiopyrimidinones
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
PH12017500637A1 (en) Inhibitors of lysine gingipain
FR3014693B1 (fr) Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
EA201591568A1 (ru) Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
FR2974364B1 (fr) Nouveaux derives amino-pyrroliniques, leur utilisation dans la prevention et/ou le traitement du syndrome metabolique
PH12015502304A1 (en) Use of pidotimod to treat irritable bowel syndrome
TN2015000433A1 (en) Use of pidotimod to treat inflammatory bowel disease

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

ST Notification of lapse

Effective date: 20200910